NO20064357L - Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease - Google Patents

Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease

Info

Publication number
NO20064357L
NO20064357L NO20064357A NO20064357A NO20064357L NO 20064357 L NO20064357 L NO 20064357L NO 20064357 A NO20064357 A NO 20064357A NO 20064357 A NO20064357 A NO 20064357A NO 20064357 L NO20064357 L NO 20064357L
Authority
NO
Norway
Prior art keywords
hepatitis
virus
inhibitors
serine protease
new compounds
Prior art date
Application number
NO20064357A
Other languages
English (en)
Norwegian (no)
Inventor
Viyyoor Moopil Girijavallabhan
Anil K Saksena
F George Njoroge
Stephane L Bogen
Kevin X Chen
Srikanth Venkatraman
Mousumi Sannigrahi
Ashok Arasappan
Frank Bennett
Angela I Padilla-Acevedo
Edwin Jao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20064357L publication Critical patent/NO20064357L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20064357A 2004-02-27 2006-09-26 Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease NO20064357L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54853504P 2004-02-27 2004-02-27
PCT/US2005/005773 WO2005087725A2 (en) 2004-02-27 2005-02-24 Novel compounds as inhibitors of hepatitis c virus ns3 serine protease

Publications (1)

Publication Number Publication Date
NO20064357L true NO20064357L (no) 2006-11-24

Family

ID=34962125

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064357A NO20064357L (no) 2004-02-27 2006-09-26 Nye forbindelser som inhibitorer for hepatitt C-virus-NS3-serinprotease

Country Status (19)

Country Link
US (2) US7186747B2 (de)
EP (2) EP1737881B1 (de)
JP (1) JP2007525511A (de)
KR (1) KR20060124729A (de)
CN (1) CN1972956A (de)
AR (1) AR047903A1 (de)
AT (2) ATE434621T1 (de)
AU (1) AU2005222056A1 (de)
BR (1) BRPI0508186A (de)
CA (1) CA2557249A1 (de)
DE (2) DE602005023224D1 (de)
EC (1) ECSP066794A (de)
ES (2) ES2349328T3 (de)
IL (1) IL177627A0 (de)
NO (1) NO20064357L (de)
RU (1) RU2006134002A (de)
TW (1) TW200529823A (de)
WO (1) WO2005087725A2 (de)
ZA (1) ZA200607053B (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130666A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Medicaments and methods combining a hcv protease inhibitor and an akr competitor
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US8119602B2 (en) 2005-06-02 2012-02-21 Schering Corporation Administration of HCV protease inhibitors in combination with food to improve bioavailability
WO2006130552A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US7772178B2 (en) * 2005-06-02 2010-08-10 Schering Corporation Pharmaceutical formulations and methods of treatment using the same
JP2008545748A (ja) * 2005-06-02 2008-12-18 シェーリング コーポレイション C型肝炎ウイルスに関連する障害を処置するために有用な徐放処方物
EP2305696A3 (de) * 2005-07-25 2011-10-12 Intermune, Inc. Makrocyclische Inhibitoren der Replikation des Hepatitis-C-Virus
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
EA200801050A1 (ru) 2005-10-11 2008-12-30 Интермьюн, Инк. Соединения и способы ингибирования репликации вирусного гепатита с
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1986177B1 (de) 2006-02-14 2011-08-03 Panasonic Corporation Verfahren zur ansteuerung einer plasmaanzeigetafel und plasmaanzeigegerät
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
US20090098085A1 (en) * 2006-08-11 2009-04-16 Ying Sun Tetrazolyl acyclic hepatitis c serine protease inhibitors
WO2008019477A1 (en) 2006-08-17 2008-02-21 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2663159A1 (en) * 2006-09-13 2008-03-20 Novartis Ag Organic compounds and their uses
US20100081672A1 (en) * 2006-12-07 2010-04-01 Schering Corporation Ph sensitive matrix formulation
US7910587B2 (en) * 2007-04-26 2011-03-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl dipeptide hepatitis C virus inhibitors
WO2008137779A2 (en) * 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2686546A1 (en) * 2007-05-10 2008-11-20 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
EP2234977A4 (de) 2007-12-19 2011-04-13 Boehringer Ingelheim Int Viren-polymerasehemmer
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
KR20110116136A (ko) 2009-01-07 2011-10-25 싸이넥시스, 인크. Hcv 및 hiv 감염의 치료에 사용하기 위한 사이클로스포린 유도체
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP2012528195A (ja) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション C型肝炎などの疾患を処置するための3つの結合アリール部分で構成された抗菌性化合物
WO2011066241A1 (en) 2009-11-25 2011-06-03 Schering Corporation Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
CA2805440A1 (en) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (de) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Kondensierte tetrazyklische derivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
WO2012142085A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (de) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido-substituierte nukleosidderivate und verfahren zu ihrer verwendung zur behandlung von virenerkrankungen
CA2840095A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Compounds for the treatment of hiv
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
WO2015065817A1 (en) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2018032467A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases
WO2018032468A1 (en) 2016-08-18 2018-02-22 Merck Sharp & Dohme Corp. Heterocycle-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases
LT3347352T (lt) 2016-08-19 2019-08-12 Gilead Sciences, Inc. Terapiniai junginiai, naudotini živ viruso infekcijos profilaktikai arba terapiniam gydymui
UY37592A (es) 2017-02-06 2018-08-31 Gilead Sciences Inc Compuestos inhibidores del vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
WO2019161017A1 (en) 2018-02-15 2019-08-22 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
KR102847339B1 (ko) 2018-02-16 2025-08-19 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
CA3157275C (en) 2019-11-26 2026-02-10 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
EP4178955A1 (de) 2020-07-11 2023-05-17 Pfizer Inc. Antivirale heteroarylketonderivate
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
AU2022403012B2 (en) 2021-12-03 2026-02-12 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
FI4440702T3 (fi) 2021-12-03 2025-08-08 Gilead Sciences Inc Terapeuttisia yhdisteitä hiv-virusinfektiota varten
AU2022399845B2 (en) 2021-12-03 2026-03-26 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN114133350B (zh) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 一种抗新冠药物Paxlovid中间体的制备方法
WO2023151188A1 (zh) * 2022-02-08 2023-08-17 上海皓元医药股份有限公司 一种抗病毒药物中间体的绿色合成方法
CN116835730B (zh) * 2023-06-15 2025-09-02 江南大学 一种用于抑制有害藻生长的双功能抑藻剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989004669A1 (en) 1987-11-18 1989-06-01 Chiron Corporation Nanbv diagnostics and vaccines
ATE132182T1 (de) 1989-02-01 1996-01-15 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche zusammensetzung auf der basis von chlorfluorkohlenwasserstoffen
AU7675491A (en) 1990-04-04 1991-10-30 Chiron Corporation Hepatitis c virus protease
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
PT1012180E (pt) 1997-08-11 2005-04-29 Boehringer Ingelheim Ca Ltd Analogos de peptidos inibidores da hepatite c
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
AU2001251165A1 (en) 2000-04-03 2001-10-15 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
HK1047947A1 (zh) 2000-04-05 2003-03-14 Schering Corporation 包含n-环状p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
AU2001253621A1 (en) 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7012066B2 (en) * 2000-07-21 2006-03-14 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
JP2002349498A (ja) * 2001-05-24 2002-12-04 Ishikawajima Harima Heavy Ind Co Ltd 低騒音ファン静翼

Also Published As

Publication number Publication date
WO2005087725A3 (en) 2005-10-27
US7425576B2 (en) 2008-09-16
IL177627A0 (en) 2006-12-31
DE602005023224D1 (de) 2010-10-07
EP1939213B1 (de) 2010-08-25
CA2557249A1 (en) 2005-09-22
ATE434621T1 (de) 2009-07-15
ATE478889T1 (de) 2010-09-15
HK1118066A1 (en) 2009-01-30
ES2349328T3 (es) 2010-12-30
ZA200607053B (en) 2009-02-25
US20050245458A1 (en) 2005-11-03
ECSP066794A (es) 2006-11-16
DE602005015093D1 (de) 2009-08-06
AU2005222056A1 (en) 2005-09-22
RU2006134002A (ru) 2008-04-10
EP1737881A2 (de) 2007-01-03
CN1972956A (zh) 2007-05-30
ES2327544T3 (es) 2009-10-30
KR20060124729A (ko) 2006-12-05
US7186747B2 (en) 2007-03-06
AR047903A1 (es) 2006-03-01
WO2005087725A2 (en) 2005-09-22
TW200529823A (en) 2005-09-16
EP1939213A1 (de) 2008-07-02
BRPI0508186A (pt) 2007-08-14
JP2007525511A (ja) 2007-09-06
HK1095837A1 (en) 2007-05-18
US20070142300A1 (en) 2007-06-21
EP1737881B1 (de) 2009-06-24

Similar Documents

Publication Publication Date Title
NO20063205L (no) Inhibitorer for hepatitt C-virus NS3/NS4A-serinprotease
NO20064356L (no) Forbindelser som inhibitorer for hepatitt C-virun-NS3-erinprotease
NO20064358L (no) Svovelforbindelser som inhibitorer for hepatitt C-virum-NS3-serinprotease
NO20064355L (no) Nye ketoamider med sykliske P4-er som inhibitorer for NS3-serinprotease fra hepatitt C-virus
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
NO20030271L (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MX2009011064A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
NO20081467L (no) Inhibitorer av sennproteaser
WO2005051980A8 (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
WO2002008198A3 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
MXPA03000627A (es) Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
NO20061822L (no) Makrosykliske inhibitorer av hepatitt C-virus-NS3-serinprotease
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
WO2008118332A3 (en) Hydrazido-peptides as inhibitors of hcv ns3-protease
WO2009008913A3 (en) P1-nonepimerizable ketoamide inhibitors of hcv ns3 protease
NO20082476L (no) Bicykliske forbindelser med kinaseinhiberende aktivitet
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
MX2009009174A (es) Inhibidores de serina-proteasas para el tratamiento de infecciones por el virus de hepatitis c.
WO2006130554A3 (en) Methods of treating hepatitis c virus
WO2010021717A3 (en) Hcv protease inhibitors
WO2010068714A3 (en) Deuterated compounds as hepatitis c virus (hcv) inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application